ArticleDermatology and therapy2025
High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe describe comorbidities and cardiovascular diseases (CVD) risk in patients with psoriasis prescribed apremilast in UK clinical practice. Such real-world data are currently sparse.
methodsThis observational, retrospective analysis of British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) included adults with plaque psoriasis first prescribed apremilast between October 2015 and March 2021. We evaluated patient comorbidities, 10-year CVD risk (Framingham risk score), time from psoriasis diagnosis, prior therapy, psoriasis severity and patient-reported quality of life (QoL) at first apremilast prescription or registry enrolment. Patient characteristics were also assessed by CVD risk and Fitzpatrick skin type.
resultsOf 265 eligible patients, 47.5% were female; median (Q1, Q3) age at first apremilast prescription was 50 (38, 60) years. The most common comorbidities were hypertension (23.4%), depression (21.5%), psoriatic arthritis (18.1%) and diabetes (15.8%). Median (Q1, Q3) time from psoriasis diagnosis to first apremilast prescription was 19 (11, 30) years; median (Q1, Q3) number of prior psoriasis therapies was 1 (1, 2). Most patients had a Physician Global Assessment score ≥ 3 (moderate/moderate-to-severe/severe disease; 75.5%), psoriasis area severity index ≥ 10 (severe/extensive disease; 82.6%), nail or scalp involvement (52.8% and 75.5%, respectively), and reported moderate or extreme pain/discomfort (57.4%) and/or a Dermatology Life Quality Index (DLQI) > 10 (large/extremely large effect; 59.2%). Among 186 patients without CVD, 63.4% had an intermediate/high 10-year risk of CVD. Patients with darker skin (Fitzpatrick skin types IV-VI) reported worse QoL than those with lighter skin (Fitzpatrick skin types IV-VI, mean [SD] DLQI, 15.7 [7.9]; I-III, 13.9 [7.8]).
conclusionsOur data indicate that patients with plaque psoriasis prescribed apremilast in UK clinical practice have a high comorbidity burden and long-term, moderate-to-severe disease with special-site involvement, uncontrolled by systemic therapy, and which had a large detrimental impact on their QoL. These data highlight the need for timely treatment with appropriate therapy following diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.